News
Displaying 11–20 of 519
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Presentation Summaries from the 10th Annual Retinal Therapy Innovation Summit
Research NewsIn its tenth year, the Innovation Summit featured 28 presentations from industry professionals worldwide and more than 400 attendees.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Research News
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
Research News
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Foundation News
The Foundation Fighting Blindness develops strategic partnership with Alma, a network of 25,000 mental health professionals dedicated to simplifying access to high-quality, affordable mental healthcare.
-
Foundation News
The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Foundation News
The partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.
-
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
Research NewsThe company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
